NR3C2 and hydrops fetalis: The pharmacotherapy of HF in study participants consisted of beta-adrenergic blockers (86.5%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor/neprilysin inhibitors (90.5%), and mineralocorticoid receptor antagonists (77.0%).